Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Arthritis, Rheumatoid | 13 | 2021 | 2043 | 1.31 | Why? |
| Antirheumatic Agents | 9 | 2021 | 3023 | 0.91 | Why? |
| Arthritis, Juvenile | 1 | 2019 | 191 | 0.64 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2018 | 2483 | 0.58 | Why? |
| Rituximab | 2 | 2018 | 1096 | 0.51 | Why? |
| Registries | 10 | 2021 | 12327 | 0.46 | Why? |
| Biological Products | 5 | 2020 | 2331 | 0.44 | Why? |
| Rheumatic Diseases | 3 | 2021 | 2675 | 0.42 | Why? |
| Rheumatology | 4 | 2021 | 1213 | 0.38 | Why? |
| Societies, Medical | 2 | 2018 | 6907 | 0.29 | Why? |
| Opportunistic Infections | 2 | 2018 | 602 | 0.22 | Why? |
| Joint Diseases | 1 | 2021 | 122 | 0.20 | Why? |
| Methotrexate | 1 | 2020 | 471 | 0.15 | Why? |
| Morbidity | 2 | 2020 | 1426 | 0.15 | Why? |
| Remission Induction | 1 | 2019 | 950 | 0.15 | Why? |
| Databases, Pharmaceutical | 1 | 2017 | 345 | 0.14 | Why? |
| Biological Therapy | 1 | 2018 | 456 | 0.13 | Why? |
| Follow-Up Studies | 6 | 2020 | 17020 | 0.11 | Why? |
| United Kingdom | 7 | 2020 | 18046 | 0.11 | Why? |
| Patient Selection | 1 | 2005 | 4560 | 0.11 | Why? |
| Medication Adherence | 1 | 2020 | 1270 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.10 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Glucocorticoids | 2 | 2021 | 4431 | 0.09 | Why? |
| Etanercept | 2 | 2018 | 162 | 0.08 | Why? |
| Clinical Medicine | 1 | 2005 | 93 | 0.07 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.06 | Why? |
| Prospective Studies | 5 | 2020 | 43301 | 0.06 | Why? |
| Infliximab | 2 | 2018 | 502 | 0.06 | Why? |
| Time Factors | 3 | 2018 | 31397 | 0.05 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.05 | Why? |
| Humans | 18 | 2021 | 930598 | 0.05 | Why? |
| Spondylarthropathies | 1 | 2020 | 163 | 0.05 | Why? |
| Certolizumab Pegol | 1 | 2018 | 36 | 0.05 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.04 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.04 | Why? |
| Social Class | 1 | 2005 | 1360 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Male | 11 | 2021 | 367725 | 0.04 | Why? |
| Prednisone | 1 | 2020 | 652 | 0.04 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.04 | Why? |
| Female | 10 | 2021 | 380317 | 0.03 | Why? |
| Rheumatologists | 1 | 2018 | 346 | 0.03 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.03 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Arthritis, Psoriatic | 1 | 2020 | 625 | 0.03 | Why? |
| Depression | 1 | 2018 | 14116 | 0.03 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.03 | Why? |
| Adalimumab | 1 | 2017 | 389 | 0.03 | Why? |
| Incidence | 3 | 2018 | 25622 | 0.03 | Why? |
| Psychometrics | 1 | 2018 | 1269 | 0.03 | Why? |
| Aged | 7 | 2021 | 215776 | 0.03 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.03 | Why? |
| Child | 1 | 2019 | 70012 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2020 | 1380 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2005 | 10649 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Adult | 4 | 2020 | 244371 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 9335 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Mental Health | 1 | 2018 | 15770 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.00 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.00 | Why? |